Recovery from diabetic macular edema in a diabetic patient after minimal dose of a sodium glucose co-transporter 2 inhibitor

American Journal of Case Reports

Volumn 19, Issue , 2018, Pages 462-466

  Yoshizumi, Hideyuki ^a   Ejima, Tetsushi ^b   Nagao, Tetsuhiko ^c   Wakisaka, Masanori ^d  

^a NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^b Fukuda Ophthalmological Hospital   (Japan)

^c Seiai Rehabilitation Hospital   (Japan)

^d Wakisaka Naika Clinic of Internal Medicine   (Japan)

Author keywords

Diabetes complications; Diabetic retinopathy; Sodium glucose transporter 2

Indexed keywords

HEMOGLOBIN A1C; IPRAGLIFLOZIN; METFORMIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; ARTICLE; BLURRED VISION; CASE REPORT; CLINICAL ARTICLE; CONVALESCENCE; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DISEASE EXACERBATION; DRUG EFFECT; FEMALE; GLYCEMIC CONTROL; HUMAN; LASER COAGULATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PROLIFERATIVE RETINOPATHY; TREATMENT DURATION; VISUAL ACUITY; COMPLICATION; MACULAR EDEMA;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MACULAR EDEMA; METFORMIN; MIDDLE AGED; SITAGLIPTIN PHOSPHATE;

EID: 85045966040     PISSN: None     EISSN: 19415923     Source Type: Journal    
DOI: 10.12659/AJCR.909708     Document Type: Article

References (23)

1. Frank RN: Diabetic retinopathy. N Engl J Med, 2004; 350(1): 48-58
2. The DCCT/EDIC Research Group: Frequency of evidence-based screening for retinopathy in type 1 diabetes. N Engl J Med, 2017; 376(16): 1507-16
3. Simó R, Hernández C: Advances in the medical treatment of diabetic retinopathy. Diabetes Care, 2009; 32(8): 1556-62
4. Serban R, Cioboata M, Chiotan C et al: Visual acuity outcome in patients with diabetic maculopathy. J Med Life, 2014; 7 Spec No.2: 71-75
5. The Diabetic Retinopathy Clinical Research Network: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med, 2015; 372(13): 1193-203
6. Mohamed Q, Gillies MC, Wong TY: Management of diabetic retinopathy: A systematic review. JAMA, 2007; 298(8): 902-16
7. Zinman B, Wanner C, Lachin JM et al: Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med, 2015; 373(22): 2117-28
8. Wanner C, Inzucchi SE, Lachin JM et al: EMPA-REG OUTCOME investigators, empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med, 2016; 375(4): 323-34
9. Neal B, Perkovic V, Mahaffey KW et al: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017; 377(7): 644-57
10. Wakisaka M: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med, 2016; 375(18): 1799-800
11. Wakisaka M, He Q, Spiro MJ et al: Glucose entry into rat mesangial cells is mediated by both Na (+)-coupled and facilitative transporters. Diabetologia, 1995; 38(3): 291-97
12. Wakisaka M, Yoshinari M, Yamamoto M et al: Na+-dependent glucose uptake and collagen synthesis by cultured bovine retinal pericytes. Biochim Biophys Acta, 1997; 1362(1): 87-96
13. Wakisaka M, Yoshinari M, Asano T et al: Normalization of glucose entry under the high glucose condition by phlorizin attenuates the high glucoseinduced morphological and functional changes of cultured bovine retinal pericytes. Biochim Biophys Acta, 1999; 1453(1): 83-91
14. Wakisaka M, Kitazono T, Kato M et al: Sodium-coupled glucose transporter as a functional glucose sensor of retinal microvascular circulation. Circ Res, 2001; 88(11): 1183-88
15. Wakisaka M, Nagao T, Yoshinari M: Sodium glucose cotransporter 2 (SGLT2) plays as physiological glucose sensor and regulates cellular contractility in rat mesangial cells. PLoS One, 2016; 11: e0151585
16. Wakisaka M, Nagao T: Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. Glycobiology, 2017; 27(8), 691-95
17. Cherney D, Lund SS, Perkins BA et al: The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia, 2016; 59(9): 1860-70
18. Bergers G, Song S: The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol, 2005; 7(4): 452-64
19. Kador PF, Akagi Y, Terubayashi H et al: Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol, 1988; 106(8): 1099-102
20. Amano S, Yamagishi SI, Kato N et al: Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem Biophys Res Commun, 2002; 299(2): 183-88
21. Brown DM, Schmidt-Erfurth U, Do DV et al: Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology, 2015; 122(10): 2044-52
22. Fong DS, Luong TQ, Contreras R et al: Treatment an analysis from large U.S. integrated health care system. Retina, 2017 [Epub ahead of print]
23. Varma R, Bressler NM, Doan QV et al: Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol, 2014; 132(11): 1334-40